Gastroenterology
Volume 135, Issue 5 , Pages 1469-1492 , November 2008

Gastrointestinal Neuroendocrine Tumors: Pancreatic Endocrine Tumors

  • David C. Metz

      Affiliations

    • Division of Gastroenterology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
    • ,
  • Robert T. Jensen

      Affiliations

    • Digestive Diseases Branch, National Institute for Diabetes and Digestive Kidney Diseases, National Institutes of Health, Bethesda, Maryland
    • Corresponding Author InformationAddress reprint requests to: Robert T. Jensen, MD, Building 10, Room 9C-103, National Institutes of Health, Bethesda, Maryland 20892. fax: (301) 402-0600

Received 4 February 2008 ,Accepted 12 May 2008.

References 

  1. Duerr EM, Chung DC. Molecular genetics of neuroendocrine tumors. Best Pract Res Clin Endocrinol Metab. 2007;21:1–14
  2. Corleto VD, Delle Fave G, Jensen RT. Molecular insights into gastrointestinal neuroendocrine tumors: importance and recent advances. Dig Liver Dis. 2002;34:668–680
  3. Arnold R. Endocrine tumors of the gastrointestinal tract: part 11. Best Practice Res Clin Gastroent. 2005;19:659–830
  4. Arnold R. Endocrine tumors of the gastrointestinal tract: part 1. Best Practice Res Clin Gastroent. 2005;19:489–656
  5. Oberg K, Eriksson BE. Neuroendocrine tumors. Best Pract Res Clin Endocrinol Metab. 2007;21:1–172
  6. de Herder WW, O'Toole D, Rindi G, et al. ENETS consensus guidelines for the management of patients with digestive neuroendocrine tumors part 1-stomach, duodenum and pancreas. Neuroendocrinology. 2006;84:151–216
  7. Plockinger U, Rindi G, Arnold R, et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours (A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS)). Neuroendocrinology. 2004;80:394–424
  8. Oberg K, Eriksson B. Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol. 2005;19:753–781
  9. Jensen RT. Endocrine neoplasms of the pancreas. In:  Yamada T,  Alpers DH,  Kaplowitz N editor. Textbook of gastroenterology. 5th ed.. Oxford: Blackwell; 2008;(in press)
  10. Ito T, Tanaka M, Sasano H, et al. Preliminary results of a Japanese nationwide survey of neuroendocrine gastrointestinal tumors. J Gastroenterol. 2007;42:497–500
  11. Panzuto F, Nasoni S, Falconi M, et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer. 2005;12:1083–1092
  12. Alexakis N, Connor S, Ghaneh P, et al. Hereditary pancreatic endocrine tumours. Pancreatology. 2004;4:417–435
  13. Jensen RT, Berna MJ, Bingham MD, et al. Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management and controversies. Cancer. 2008;(in press)
  14. Kloppel G. Tumour biology and histopathology of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab. 2007;21:15–31
  15. Brignardello E, Manti R, Papotti M, et al. Ectopic secretion of LH by an endocrine pancreatic tumor. J Endocrinol Invest. 2004;27:361–365
  16. Samyn I, Fontaine C, Van Tussenbroek F, et al. Paraneoplastic syndromes in cancer: case 1 (Polycythemia as a result of ectopic erythropoietin production in metastatic pancreatic carcinoid tumor). J Clin Oncol. 2004;22:2240–2242
  17. Kawano K, Ushijima K, Fujimoto T, et al. Peptide YY producing strumal carcinoid of the ovary as the cause of severe constipation with contralateral epithelial ovarian cancer. J Obstet Gynaecol Res. 2007;33:392–396
  18. Kloppel G, Anlauf M. Epidemiology, tumour biology and histopathological classification of neuroendocrine tumours of the gastrointestinal tract. Best Pract Res Clin Gastroenterol. 2005;19:507–517
  19. Rindi G, Kloppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006;449:395–401
  20. Rindi G, Bordi C. Aetiology, molecular pathogenesis and genetics. Best Pract Res Clin Gastroenterol. 2005;19:519–534
  21. Chandrasekharappa SC, Guru SC, Manickam P, et al. Positional cloning of the gene for multiple endocrine neoplasia—-type 1. Science. 1997;276:404–407
  22. Busygina V, Bale AE. Multiple endocrine neoplasia type 1 (MEN1) as a cancer predisposition syndrome: clues into the mechanisms of MEN1-related carcinogenesis. Yale J Biol Med. 2006;79:105–114
  23. Goebel SU, Heppner C, Burns AD, et al. Genotype/phenotype correlations of MEN1 gene mutations in sporadic gastrinoma. J Clin Endocrinol Metab. 2000;85:116–123
  24. Debelenko LV, Zhuang ZP, Emmert-Buck MR, et al. Allelic deletions on chromosome 11q13 in multiple endocrine neoplasia type-I-associated sporadic gastrinomas and pancreatic endocrine tumors. Cancer Res. 1997;57:2238–2243
  25. Perren A, Komminoth P, Heitz PU. Molecular genetics of gastroenteropancreatic endocrine tumors. Ann N Y Acad Sci. 2004;1014:199–208
  26. Capurso G, Lattimore S, Crnogorac-Jurcevic T, et al. Gene expression profiles of progressive pancreatic endocrine tumours and their liver metastases reveal potential novel markers and therapeutic targets. Endocr Relat Cancer. 2006;13:541–558
  27. Dilley WG, Kalyanaraman S, Verma S, et al. Global gene expression in neuroendocrine tumors from patients with the MEN1 syndrome. Mol Cancer. 2005;4:9
  28. Hansel DE, Rahman A, House M, et al. Met proto-oncogene and insulin-like growth factor binding protein 3 overexpression correlates with metastatic ability in well-differentiated pancreatic endocrine neoplasms. Clin Cancer Res. 2004;10:6152–6158
  29. Maitra A, Hansel DE, Argani P, et al. Global expression analysis of well-differentiated pancreatic endocrine neoplasms using oligonucleotide microarrays. Clin Cancer Res. 2003;9:5988–5995
  30. Hoffmann KM, Furukawa M, Jensen RT. Duodenal neuroendocrine tumors: classification, functional syndromes, diagnosis and medical treatment. Best Pract Res Clin Gastroenterol. 2005;19:675–697
  31. Jensen RT, Niederle B, Mitry E, et al. Gastrinoma (duodenal and pancreatic). Neuroendocrinology. 2006;84:173–182
  32. Thom AK, Norton JA, Axiotis CA, et al. Location, incidence and malignant potential of duodenal gastrinomas. Surgery. 1991;110:1086–1093
  33. Jensen RT. Natural history of digestive endocrine tumors. In:  Mignon M,  Colombel JF editor. Recent advances in pathophysiology and management of inflammatory bowel diseases and digestive endocrine tumors. Paris, France: John Libbey Eurotext Publishing Co; 1999;p. 192–219
  34. Gibril F, Doppman JL, Reynolds JC, et al. Bone metastases in patients with gastrinomas: a prospective study of bone scanning, somatostatin receptor scanning, and MRI in their detection, their frequency, location and effect of their detection on management. J Clin Oncol. 1998;16:1040–1053
  35. Yu F, Venzon DJ, Serrano J, et al. Prospective study of the clinical course, prognostic factors and survival in patients with longstanding Zollinger-Ellison syndrome. J Clin Oncol. 1999;17:615–630
  36. Weber HC, Venzon DJ, Lin JT, et al. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology. 1995;108:1637–1649
  37. Sutliff VE, Doppman JL, Gibril F, et al. Growth of newly diagnosed, untreated metastatic gastrinomas and predictors of growth patterns. J Clin Oncol. 1997;15:2420–2431
  38. Madeira I, Terris B, Voss M, et al. Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. Gut. 1998;43:422–427
  39. Soga J, Yakuwa Y. Vipoma/diarrheogenic syndrome: a statistical evaluation of 241 reported cases. J Exp Clin Cancer Res. 1998;17:389–400
  40. Nesi G, Marcucci T, Rubio CA, et al. Somatostatinoma: clinico-pathological features of three cases and literature reviewed. J Gastroenterol Hepatol. 2008;23:521–526
  41. Chu QD, Hill HC, Douglass HO, et al. Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas. Ann Surg Oncol. 2002;9:855–862
  42. La Rosa S, Sessa F, Capella C, et al. Prognostic criteria in nonfunctioning pancreatic endocrine tumours. Virchows Arch. 1996;429:323–333
  43. Hochwald SN, Zee S, Conlon KC, et al. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol. 2002;20:2633–2642
  44. Maton PN, Gardner JD, Jensen RT. Cushing's syndrome in patients with Zollinger-Ellison syndrome. N Engl J Med. 1986;315:1–5
  45. Jensen RT, Gardner JD. Gastrinoma. In:  Go VLW,  DiMagno EP,  Gardner JD, et al. editor. The pancreas: biology, pathobiology and disease. 2nd ed.. New York: Raven Press Publishing Co; 1993;p. 931–978
  46. Norton JA, Sugarbaker PH, Doppman JL, et al. Aggressive resection of metastatic disease in selected patients with malignant gastrinoma. Ann Surg. 1986;203:352–359
  47. Guillausseau PJ, Guillausseau-Scholer C. Glucagonomas: clinical presentation, diagnosis, and advances in management. In:  Mignon M,  Jensen RT editor. Endocrine tumors of the pancreas: recent advances in research and management. Series: frontiers in gastrointestinal research. Volume 23. Basel, Switzerland: S. Karger; 1995;p. 183–193
  48. Thompson GB, Van Heerden JA, Grant CS, et al. Islet cell carcinomas of the pancreas: a twenty-year experience. Surgery. 1988;104:1011–1017
  49. Lo CY, Van Heerden JA, Thompson GB, et al. Islet cell carcinoma of the pancreas. World J Surg. 1996;20:878–884
  50. Norton JA, Fraker DL, Alexander HR, et al. Surgery increases survival in patients with gastrinoma. Ann Surg. 2006;244:410–419
  51. Fraker DL, Norton JA, Alexander HR, et al. Surgery in Zollinger-Ellison syndrome alters the natural history of gastrinoma. Ann Surg. 1994;220:320–330
  52. de Herder WW. Biochemistry of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab. 2007;21:33–41
  53. Gibril F, Jensen RT. Zollinger-Ellison syndrome revisited: diagnosis, biologic markers, associated inherited disorders, and acid hypersecretion. Curr Gastroenterol Rep. 2004;6:454–463
  54. Nobels FR, Kwekkeboom DJ, Coopmans W, et al. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab. 1997;82:2622–2628
  55. Campana D, Nori F, Piscitelli L, et al. Chromogranin A: is it a useful marker of neuroendocrine tumors?. J Clin Oncol. 2007;25:1967–1973
  56. Zatelli MC, Torta M, Leon A, et al. Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study. Endocr Relat Cancer. 2007;14:473–482
  57. Perren A, Anlauf M, Henopp T, et al. Multiple endocrine neoplasia type 1 (MEN1): loss of one MEN1 allele in tumors and monohormonal endocrine cell clusters but not in islet hyperplasia of the pancreas. J Clin Endocrinol Metab. 2007;92:1118–1128
  58. Baudin E. Gastroenteropancreatic endocrine tumors: clinical characterization before therapy. Nat Clin Pract Endocrinol Metab. 2007;3:228–239
  59. Roy P, Venzon DJ, Feigenbaum KM, et al. Gastric secretion in Zollinger-Ellison syndrome: correlation with clinical expression, tumor extent and role in diagnosis—a prospective NIH study of 235 patients and review of the literature in 984 cases. Medicine (Baltimore). 2001;80:189–222
  60. Soga J, Yakuwa Y. The gastrinoma/Zollinger-Ellison syndrome: statistical evaluation of a Japanese series of 359 cases. J Hepatobiliary Pancreat Surg. 1998;5:77–85
  61. Roy P, Venzon DJ, Shojamanesh H, et al. Zollinger-Ellison syndrome: clinical presentation in 261 patients. Medicine (Baltimore). 2000;79:379–411
  62. Jensen RT, Doppman JL, Gardner JD. Gastrinoma. In:  Go VLW,  Brooks FA,  DiMagno EP, et al. editor. The exocrine pancreas: biology, pathobiology and disease. 1st ed.. New York: Raven Press; 1986;p. 727–744
  63. Benya RV, Metz DC, Venzon DJ, et al. Zollinger-Ellison syndrome can be the initial endocrine manifestation in patients with multiple endocrine neoplasia-type 1. Am J Med. 1994;97:436–444
  64. Gibril F, Schumann M, Pace A, et al. Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome (A prospective study of 107 cases and comparison with 1009 patients from the literature). Medicine (Baltimore). 2004;83:43–83
  65. Hou W, Schubert ML. Gastric secretion. Curr Opin Gastroenterol. 2006;22:593–598
  66. Corleto VD, Annibale B, Gibril F, et al. Does the widespread use of proton pump inhibitors mask, complicate and/or delay the diagnosis of Zollinger-Ellison syndrome?. Aliment Pharmacol Ther. 2001;15:1555–1561
  67. Berna MJ, Hoffmann KM, Serrano J, et al. Serum gastrin in Zollinger-Ellison syndrome: I (Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature). Medicine (Baltimore). 2006;85:295–330
  68. Ruszniewski P, Podevin P, Cadiot G, et al. Clinical, anatomical, and evolutive features of patients with the Zollinger-Ellison syndrome combined with type I multiple endocrine neoplasia. Pancreas. 1993;8:295–304
  69. Berna MJ, Hoffmann KM, Long SH, et al. Serum gastrin in Zollinger-Ellison syndrome: II (Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. evaluation of diagnostic criteria, proposal of new criteria, and correlations with clinical and tumoral features). Medicine (Baltimore). 2006;85:331–364
  70. Gibril F, Lindeman RJ, Abou-Saif A, et al. Retained gastric antrum syndrome (A forgotten, treatable cause of refractory peptic ulcer disease). Dig Dis Sci. 2001;46:610–617
  71. McGuigan JE, Wolfe MM. Secretin injection test in the diagnosis of gastrinoma. Gastroenterology. 1980;79:1324–1331
  72. Frucht H, Howard JM, Slaff JI, et al. Secretin and calcium provocative tests in the Zollinger-Ellison syndrome: a prospective study. Ann Intern Med. 1989;111:713–722
  73. Norton JA, Cornelius MJ, Doppman JL, et al. Effect of parathyroidectomy in patients with hyperparathyroidism, Zollinger-Ellison syndrome and multiple endocrine neoplasia type I: a prospective study. Surgery. 1987;102:958–966
  74. Jensen RT. Management of the Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia type 1. J Intern Med. 1998;243:477–488
  75. Norton JA, Venzon DJ, Berna MJ, et al. Prospective study of surgery for primary hyperaparathyroidism (HPT) in multiple endocrine neoplasia type 1 (MEN1), and Zollinger-Ellison syndrome (ZES): longterm outcome of a more virulent form of HPT. Ann Surgery. 2008;247:501–510
  76. Grant CS. Insulinoma. Best Pract Res Clin Gastroenterol. 2005;19:783–798
  77. de Herder WW, Niederle B, Scoazec JY, et al. Well-differentiated pancreatic tumor/carcinoma: insulinoma. Neuroendocrinology. 2006;84:183–188
  78. Vezzosi D, Bennett A, Fauvel J, et al. Insulin levels measured with an insulin-specific assay in patients with fasting hypoglycaemia related to endogenous hyperinsulinism. Eur J Endocrinol. 2003;149:413–419
  79. Vezzosi D, Bennet A, Fauvel J, et al. Insulin, C-peptide and proinsulin for the biochemical diagnosis of hypoglycaemia related to endogenous hyperinsulinism. Eur J Endocrinol. 2007;157:75–83
  80. Soga J, Yakuwa Y. Glucagonomas/diabetico-dermatogenic syndrome (DDS): a statistical evaluation of 407 reported cases. J Hepatobiliary Pancreat Surg. 1998;5:312–319
  81. van Beek AP, de Haas ER, van Vloten WA, et al. The glucagonoma syndrome and necrolytic migratory erythema: a clinical review. Eur J Endocrinol. 2004;151:531–537
  82. Kindmark H, Sundin A, Granberg D, et al. Endocrine pancreatic tumors with glucagon hypersecretion: a retrospective study of 23 cases during 20 years. Med Oncol. 2007;24:330–337
  83. Wald M, Lawrenz K, Luckner D, et al. Glucagon therapy as a possible cause of erythema necrolyticum migrans in two neonates with persistent hyperinsulinaemic hypoglycaemia. Eur J Pediatr. 2002;161:600–603
  84. Case CC, Vassilopoulou-Sellin R. Reproduction of features of the glucagonoma syndrome with continuous intravenous glucagon infusion as therapy for tumor-induced hypoglycemia. Endocr Pract. 2003;9:22–25
  85. Mullans EA, Cohen PR. Iatrogenic necrolytic migratory erythema: a case report and review of nonglucagonoma-associated necrolytic migratory erythema. J Am Acad Dermatol. 1998;38:866–873
  86. Appetecchia M, Ferretti E, Carducci M, et al. Malignant glucagonoma (New options of treatment). J Exp Clin Cancer Res. 2006;25:135–139
  87. Matuchansky C, Rambaud JC. VIPomas and endocrine cholera: clinical presentation, diagnosis, and advances in management. In:  Mignon M,  Jensen RT editor. Endocrine tumors of the pancreas: recent advances in research and management. Series: frontiers in gastrointestinal research. Volume 23:Basel, Switzerland: S. Karger; 1995;p. 166–182
  88. Nikou GC, Toubanakis C, Nikolaou P, et al. VIPomas: an update in diagnosis and management in a series of 11 patients. Hepatogastroenterology. 2005;52:1259–1265
  89. Ghaferi AA, Chojnacki KA, Long WD, et al. Pancreatic VIPomas: subject review and one institutional experience. J Gastrointest Surg. 2008;12:382–393
  90. Jensen RT. Diarrhea in neuroendocrine disorders. In:  Domschke W,  Stoll R,  Brasitus TA, et al. editor. Intestinal mucosa and its diseases: pathophysiology and clinics. 110th ed.. Dordrecht, The Netherlands: Kluwer Academic Publishers BV; 1999;p. 61–76
  91. Krejs GJ, Orci L, Conlon JM, et al. Somatostatinoma syndrome (Biochemical, morphologic and clinical features). N Engl J Med. 1979;301:285–292
  92. Moayedoddin B, Booya F, Wermers RA, et al. Spectrum of malignant somatostatin-producing neuroendocrine tumors. Endocr Pract. 2006;12:394–400
  93. Tanaka S, Yamasaki S, Matsushita S, et al. Duodenal somatostatinoma: a case report and review of 31 cases with special reference to the relationship between tumor size and metastasis. Pathol Int. 2000;50:146–152
  94. Losa M, von Werder K. Pathophysiology and clinical aspects of the ectopic GH-releasing hormone syndrome. Clin Endocrinol. 1997;47:123–135
  95. Sano T, Asa SL, Kovacs K. Growth hormone-releasing hormone-producing tumors: clinical, biochemical, and morphological manifestations. Endocr Rev. 1988;9:357–373
  96. Gola M, Doga M, Bonadonna S, et al. Neuroendocrine tumors secreting growth hormone-releasing hormone: pathophysiological and clinical aspects. Pituitary. 2006;9:221–229
  97. Falconi M, Plockinger U, Kwekkeboom DJ, et al. Well-differentiated pancreatic nonfunctioning tumors/carcinoma. Neuroendocrinology. 2006;84:196–211
  98. Plockinger U, Wiedenmann B. Diagnosis of non-functioning neuro-endocrine gastro-enteropancreatic tumours. Neuroendocrinology. 2004;80(Suppl 1):35–38
  99. Gullo L, Migliori M, Falconi M, et al. Nonfunctioning pancreatic endocrine tumors: a multicenter clinical study. Am J Gastroenterol. 2003;98:2435–2439
  100. Eriksson B, Oberg K. PPomas and nonfunctioning endocrine pancreatic tumors: clinical presentation, diagnosis, and advances in management. In:  Mignon M,  Jensen RT editor. Endocrine tumors of the pancreas: recent advances in research and management. Series: frontiers in gastrointestinal research. Volume 23:Basel, Switzerland: S. Karger; 1995;p. 208–222
  101. Hochwald SN, Conlon KC, Brennan MF. Nonfunctional pancreatic islet cell tumors. In:  Doherty GM,  Skogseid B editor. Surgical endocrinology. Philadelphia: Lippincott Williams & Wilkins; 2001;p. 361–373
  102. Brennan MF, Marx SJ, Doppman J, et al. Results of reoperation for persistent and recurrent hyperparathyroidism. Ann Surg. 1981;194:671–676
  103. Plockinger U, Wiedenmann B. Management of metastatic endocrine tumours. Best Pract Res Clin Gastroenterol. 2005;19:553–576
  104. Gibril F, Jensen RT. Diagnostic uses of radiolabelled somatostatin-receptor analogues in gastroenteropancreatic endocrine tumors. Dig Liver Dis. 2004;36:S106–S120
  105. Rockall AG, Reznek RH. Imaging of neuroendocrine tumours (CT/MR/US). Best Pract Res Clin Endocrinol Metab. 2007;21:43–68
  106. Sundin A, Garske U, Orlefors H. Nuclear imaging of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab. 2007;21:69–85
  107. Noone TC, Hosey J, Firat Z, et al. Imaging and localization of islet-cell tumours of the pancreas on CT and MRI. Best Pract Res Clin Endocrinol Metab. 2005;19:195–211
  108. Wiedenmann B, Jensen RT, Mignon M, et al. Preoperative diagnosis and surgical management of neuroendocrine gastroenteropancreatic tumors: general recommendations by a consensus workshop. World J Surg. 1998;22:309–318
  109. Orbuch M, Doppman JL, Strader DB, et al. Imaging for pancreatic endocrine tumor localization: recent advances. In:  Mignon M,  Jensen RT editor. Endocrine tumors of the pancreas: recent advances in research and management. Frontiers in gastrointestinal research. Volume 23:Basel, Switzerland: S. Karger; 1995;p. 268–281
  110. Krudy AG, Doppman JL, Jensen RT, et al. Localization of islet cell tumors by dynamic CT: comparison with plain CT, arteriography, sonography and venous sampling. AJR Am J Roentgenol. 1984;143:585–589
  111. Frucht H, Doppman JL, Norton JA, et al. Gastrinomas: comparison of MR imaging with CT, angiography and US. Radiology. 1989;171:713–717
  112. Orbuch M, Doppman JL, Jensen RT. Localization of pancreatic endocrine tumors (Pancreatic endocrine tumors). Semin Gastrointest Dis. 1995;6:90–101
  113. Akerstrom G, Hellman P. Surgery on neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab. 2007;21:87–109
  114. Ho JM, Darcy SJ, Eysselein VE, et al. Evolution of fine needle aspiration cytology in the accurate diagnosis of pancreatic neoplasms. Am Surg. 2007;73:941–944
  115. Nichols MT, Russ PD, Chen YK. Pancreatic imaging: current and emerging technologies. Pancreas. 2006;33:211–220
  116. Pausawasdi N, Scheiman J. Endoscopic evaluation and palliation of pancreatic adenocarcinoma: current and future options. Curr Opin Gastroenterol. 2007;23:515–521
  117. McLean AM, Fairclough PD. Endoscopic ultrasound in the localisation of pancreatic islet cell tumours. Best Pract Res Clin Endocrinol Metab. 2005;19:177–193
  118. DeAngelis C, Carucci P, Repici A, et al. Endosonography in decision making and management of gastrointestinal endocrine tumors. Eur J Ultrasound. 1999;10:139–150
  119. Chang F, Chandra A, Culora G, et al. Cytologic diagnosis of pancreatic endocrine tumors by endoscopic ultrasound-guided fine-needle aspiration: a review. Diagn Cytopathol. 2006;34:649–658
  120. Stelow EB, Woon C, Pambuccian SE, et al. Fine-needle aspiration cytology of pancreatic somatostatinoma: the importance of immunohistochemistry for the cytologic diagnosis of pancreatic endocrine neoplasms. Diagn Cytopathol. 2005;33:100–105
  121. Norton JA, Jensen RT. Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg. 2004;240:757–773
  122. Zimmer T, Stolzel U, Bader M, et al. Endoscopic ultrasonography and somatostatin receptor scintigraphy in the preoperative localisation of insulinomas and gastrinomas. Gut. 1996;39:562–568
  123. Vezzosi D, Bennet A, Rochaix P, et al. Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies. Eur J Endocrinol. 2005;152:757–767
  124. Bertherat J, Tenenbaum F, Perlemoine K, et al. Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study. J Clin Endocrinol Metab. 2003;88:5353–5360
  125. Langer P, Kann PH, Fendrich V, et al. Prospective evaluation of imaging procedures for the detection of pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1. World J Surg. 2004;28:1317–1322
  126. Wamsteker EJ, Gauger PG, Thompson NW, et al. EUS detection of pancreatic endocrine tumors in asymptomatic patients with type 1 multiple endocrine neoplasia. Gastrointest Endosc. 2003;58:531–535
  127. Kann PH, Balakina E, Ivan D, et al. Natural course of small, asymptomatic neuroendocrine pancreatic tumours in multiple endocrine neoplasia type 1: an endoscopic ultrasound imaging study. Endocr Relat Cancer. 2006;13:1195–1202
  128. Hellman P, Hennings J, Akerstrom G, et al. Endoscopic ultrasonography for evaluation of pancreatic tumours in multiple endocrine neoplasia type 1. Br J Surg. 2005;92:1508–1512
  129. Langer P, Wild A, Celik I, et al. Prospective controlled trial of a standardized meal stimulation test in the detection of pancreaticoduodenal endocrine tumours in patients with multiple endocrine neoplasia type 1. Br J Surg. 2001;88:1403–1407
  130. Kann PH, Kann B, Fassbender WJ, et al. Small neuroendocrine pancreatic tumors in multiple endocrine neoplasia type 1 (MEN1): least significant change of tumor diameter as determined by endoscopic ultrasound (EUS) imaging. Exp Clin Endocrinol Diabetes. 2006;114:361–365
  131. Lonser RR, Glenn GM, Walther M, et al. von Hippel-Lindau disease. Lancet. 2003;361:2059–2067
  132. Hammel PR, Vilgrain V, Terris B, et al. Pancreatic involvement in von Hippel-Lindau disease. Gastroenterology. 2000;119:1087–1095
  133. Libutti SK, Choyke PL, Alexander HR, et al. Clinical and genetic analysis of patients with pancreatic neuroendocrine tumors associated with von Hippel-Lindau disease. Surgery. 2000;128:1022–1027
  134. Binkovitz LA, Johnson CD, Stephens DH. Islet cell tumors in von Hippel-Lindau disease: increased prevalence and relationship to the multiple endocrine neoplasias. AJR Am J Roentgenol. 1990;155:501–505
  135. Libutti SK, Choyke PL, Bartlett DL, et al. Pancreatic neuroendocrine tumors associated with von Hippel Lindau disease: diagnostic and management recomendations. Surgery. 1998;124:1153–1159
  136. Marcos HB, Libutti SK, Alexander HR, et al. Neuroendocrine tumors of the pancreas in von Hippel-Lindau disease: spectrum of appearances at CT and MR imaging with histopathologic comparison. Radiology. 2002;225:751–758
  137. Blansfield JA, Choyke L, Morita SY, et al. Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Surgery. 2007;142:814–818
  138. Wermer P. Genetic aspects of adenomatosis of endocrine glands. Am J Med. 1954;16:363–371
  139. Strader DB, Doppman JL, Orbuch M, et al. Functional localization of pancreatic endocrine tumors. In:  Mignon M,  Jensen RT editor. Endocrine tumors of the pancreas: recent advances in research and management. Series: frontiers in gastrointestinal research. Volume 23:Basel, Switzerland: Karger Publishing Co; 1995;p. 282–297
  140. Jackson JE. Angiography and arterial stimulation venous sampling in the localization of pancreatic neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab. 2005;19:229–239
  141. Gibril F, Doppman JL, Chang R, et al. Metastatic gastrinomas: localization with selective arterial injection of secretin. Radiology. 1996;198:77–84
  142. Miller DL, Doppman JL, Metz DC, et al. Zollinger-Ellison syndrome: technique, results and complications of portal venous sampling. Radiology. 1992;182:235–241
  143. Thom AK, Norton JA, Doppman JL, et al. Prospective study of the use of intraarterial secretin injection and portal venous sampling to localize duodenal gastrinomas. Surgery. 1992;112:1002–1008
  144. Doppman JL, Miller DL, Chang R, et al. Gastrinomas: localization by means of selective intraarterial injection of secretin. Radiology. 1990;174:25–29
  145. Lo CY, Chan FL, Tam SC, et al. Value of intra-arterial calcium stimulated venous sampling for regionalization of pancreatic insulinomas. Surgery. 2000;128:903–909
  146. Piovesan A, Pia A, Visconti G, et al. Proinsulin-secreting neuroendocrine tumor of the pancreas. J Endocrinol Invest. 2003;26:758–761
  147. Doppman JL, Chang R, Fraker DL, et al. Localization of insulinomas to regions of the pancreas by intra-arterial stimulation with calcium. Ann Intern Med. 1995;123:269–273
  148. Defreyne L, Konig K, Lerch MM, et al. Modified intra-arterial calcium stimulation with venous sampling test for preoperative localization of insulinomas. Abdom Imaging. 1998;23:322–331
  149. Baba Y, Miyazono N, Nakajo M, et al. Localization of insulinomas (Comparison of conventional arterial stimulation with venous sampling (ASVS) and superselective ASVS). Acta Radiol. 2000;41:172–177
  150. Guillermet-Guibert J, Lahlou H, Pyronnet S, et al. Somatostatin receptors as tools for diagnosis and therapy: molecular aspects. Best Pract Res Clin Gastroenterol. 2005;19:535–551
  151. Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20:716–731
  152. Papotti M, Bonjiovanni M, Volante M, et al. Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. Virchows Arch. 2002;440:461–475
  153. Jensen RT. Peptide therapy. Recent advances in the use of somatostatin and other peptide receptor agonists and antagonists. In:  Lewis JH,  Dubois A editor. Current clinical topics in gastrointestinal pharmacology. Malden, MA: Blackwell Science, Inc; 1997;p. 144–223
  154. Virgolini I, Traub-Weidinger T, Decristoforo C. Nuclear medicine in the detection and management of pancreatic islet-cell tumours. Best Pract Res Clin Endocrinol Metab. 2005;19:213–227
  155. Gibril F, Reynolds JC, Doppman JL, et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas: a prospective study. Ann Intern Med. 1996;125:26–34
  156. Termanini B, Gibril F, Doppman JL, et al. Distinguishing small hepatic hemangiomas from vascular liver metastases in patients with gastrinoma: use of a somatostatin-receptor scintigraphic agent. Radiology. 1997;202:151–158
  157. Schillaci O, Spanu A, Scopinaro F, et al. Somatostatin receptor scintigraphy in liver metastasis detection from gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2003;44:359–368
  158. Lebtahi R, Cadiot G, Delahaye N, et al. Detection of bone metastases in patients with endocrine gastroenteropancreatic tumors: bone scintigraphy compared with somatostatin receptor scintigraphy. J Nucl Med. 1999;40:1602–1608
  159. Schillaci O, Corleto VD, Annibale B, et al. Single photon emission computed tomography procedure improves accuracy of somatostatin receptor scintigraphy in gastro-entero pancreatic tumours. Ital J Gastroenterol Hepatol. 1999;31:S186–S189
  160. Lebtahi R, Cadiot G, Sarda L, et al. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med. 1997;38:853–858
  161. Termanini B, Gibril F, Reynolds JC, et al. Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management. Gastroenterology. 1997;112:335–347
  162. Cadiot G, Bonnaud G, Lebtahi R, et al. Usefulness of somatostatin receptor scintigraphy in the management of patients with Zollinger-Ellison syndrome. Gut. 1997;41:107–114
  163. Alexander HR, Fraker DL, Norton JA, et al. Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome. Ann Surg. 1998;228:228–238
  164. Eriksson B, Orlefors H, Oberg K, et al. Developments in PET for the detection of endocrine tumours. Best Pract Res Clin Endocrinol Metab. 2005;19:311–324
  165. Gabriel M, Decristoforo C, Kendler D, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48:508–518
  166. Orlefors H, Sundin A, Garske U, et al. Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab. 2005;90:3392–3400
  167. Metz DC, Jensen RT. Advances in gastric antisecretory therapy in Zollinger-Ellison syndrome. In:  Mignon M,  Jensen RT editor. Endocrine tumors of the pancreas: recent advances in research and management. Series: frontiers in gastrointestinal research. Volume 23:Basel, Switzerland: S. Karger; 1995;p. 240–257
  168. Berna MJ, Jensen RT. Role of CCK/gastrin receptors in gastrointestinal/metabolic diseases and results of human studies using gastrin/CCK receptor agonists/antagonists in these diseases. Curr Top Med Chem. 2007;7:1211–1231
  169. Jensen RT. Use of omeprazole and other proton pump inhibitors in the Zollinger-Ellison syndrome. In:  Olbe L editors. Milestones in drug therapy. Basel, Switzerland: Birkhauser Verlag AG Publish. Co; 1999;p. 205–221
  170. Metz DC, Strader DB, Orbuch M, et al. Use of omeprazole in Zollinger-Ellison: a prospective nine-year study of efficacy and safety. Aliment Pharmacol Ther. 1993;7:597–610
  171. Metz DC, Pisegna JR, Ringham GL, et al. Prospective study of efficacy and safety of lansoprazole in Zollinger-Ellison syndrome. Dig Dis Sci. 1993;38:245–256
  172. Hirschowitz BI, Simmons J, Mohnen J. Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study. Clin Gastroenterol Hepatol. 2005;3:39–48
  173. Metz DC, Comer GM, Soffer E, et al. Three-year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditions. Aliment Pharmacol Ther. 2006;23:437–444
  174. Morocutti A, Merrouche M, Bjaaland T, et al. An open-label study of rabeprazole in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion. Aliment Pharmacol Ther. 2006;24:1439–1444
  175. Metz DC, Sostek MB, Ruszniewski P, et al. Effects of esomeprazole on acid output in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion. Am J Gastroenterol. 2007;102:2648–2654
  176. Raufman JP, Collins SM, Pandol SJ, et al. Reliability of symptoms in assessing control of gastric acid secretion in patients with Zollinger-Ellison syndrome. Gastroenterology. 1983;84:108–113
  177. Miller LS, Vinayek R, Frucht H, et al. Reflux esophagitis in patients with Zollinger-Ellison syndrome. Gastroenterology. 1990;98:341–346
  178. Maton PN, Frucht H, Vinayek R, et al. Medical management of patients with Zollinger-Ellison syndrome who have had previous gastric surgery: a prospective study. Gastroenterology. 1988;94:294–299
  179. Metz DC, Pisegna JR, Fishbeyn VA, et al. Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high. Gastroenterology. 1992;103:1498–1508
  180. Termanini B, Gibril F, Stewart CA, et al. A prospective study of the effectiveness of low dose omeprazole as initial therapy in Zollinger-Ellison syndrome. Aliment Pharmacol Ther. 1996;10:61–71
  181. Termanini B, Gibril F, Sutliff VE, et al. Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome. Am J Med. 1998;104:422–430
  182. Stewart CA, Termanini B, Sutliff VE, et al. Assessment of the risk of iron malabsorption in patients with Zollinger-Ellison syndrome treated with long-term gastric acid antisecretory therapy. Aliment Pharmacol Ther. 1998;12:83–98
  183. Peghini PL, Annibale B, Azzoni C, et al. Effect of chronic hypergastrinemia on human enterochromaffin-like cells: insights from patients with sporadic gastrinomas. Gastroenterology. 2002;123:68–85
  184. Maton PN, Lack EE, Collen MJ, et al. The effect of Zollinger-Ellison syndrome and omeprazole therapy on gastric oxyntic endocrine cells. Gastroenterology. 1990;99:943–950
  185. Berna MJ, Annibale B, Marignani M, et al. A prospective study of gastric carcinoids and enterochromaffin-like cells changes in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: identification of risk factors. J Clin Endocrinol Metab. 2008;93:1582–1591
  186. Lehy T, Cadiot G, Mignon M, et al. Influence of multiple endocrine neoplasia type 1 on gastric endocrine cells in patients with the Zollinger-Ellison syndrome. Gut. 1992;33:1275–1279
  187. Bordi C, Azzoni C, Ferraro G, et al. Sampling strategies for analysis of enterochromaffin-like cell changes in Zollinger-Ellison syndrome. Am J Clin Pathol. 2000;114:419–425
  188. Lew EA, Pisegna JR, Starr JA, et al. Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Gastroenterology. 2000;118:696–704
  189. Schumacher B, Lubke HJ, Frieling T, et al. Prospective study on the detection of insulinomas by endoscopic ultrasonography. Endoscopy. 1996;28:273–276
  190. Creutzfeldt W. Insulinomas: clinical presentation, diagnosis, and advances in management. In:  Mignon M,  Jensen RT editor. Endocrine tumors of the pancreas: recent advances in research and management. Series: frontiers in gastrointestinal research. Volume 23:Basel, Switzerland: S. Karger; 1995;p. 148–165
  191. Gill GV, Rauf O, MacFarlane IA. Diazoxide treatment for insulinoma: a national UK survey. Postgrad Med J. 1997;73:640–641
  192. Pless J, Bauer W, Briner U, et al. Chemistry and pharmacology of SMS 201-995, a long-acting octapeptide analogue of somatostatin. Scand J Gastroenterol Suppl. 1986;119:54–64
  193. Maton PN, Gardner JD, Jensen RT. Use of the long-acting somatostatin analog, SMS 201-995 in patients with pancreatic islet cell tumors. Dig Dis Sci. 1989;34:28S–39S
  194. McKeage K, Cheer S, Wagstaff AJ. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly. Drugs. 2003;63:2473–2499
  195. Bajetta E, Procopio G, Catena L, et al. Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a phase III study. Cancer. 2006;107:2474–2481
  196. Newman CB, Melmed S, Snyder PJ, et al. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients—a clinical research center study. J Clin Endocrinol Metab. 1995;80:2768–2775
  197. Norton JA, Alexander HR, Fraker DL, et al. Comparison of surgical results in patients with advanced and limited disease with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. Ann Surg. 2001;234:495–506
  198. Norton JA, Fraker DL, Alexander HR, et al. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med. 1999;341:635–644
  199. Fishbeyn VA, Norton JA, Benya RV, et al. Assessment and prediction of long-term cure in patients with Zollinger-Ellison syndrome: the best approach. Ann Intern Med. 1993;119:199–206
  200. Hiramoto JS, Feldstein VA, LaBerge JM, et al. Intraoperative ultrasound and preoperative localization detects all occult insulinomas. Arch Surg. 2001;136:1020–1026
  201. Norton JA. Surgical treatment of neuroendocrine metastases. Best Pract Res Clin Gastroenterol. 2005;19:577–583
  202. Que FG, Sarmiento JM, Nagorney DM. Hepatic surgery for metastatic gastrointestinal neuroendocrine tumors. Adv Exp Med Biol. 2006;574:43–56
  203. Norton JA, Doherty GD, Fraker DL, et al. Surgical treatment of localized gastrinoma within the liver: a prospective study. Surgery. 1998;124:1145–1152
  204. Norton JA, Warren RS, Kelly MG, et al. Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery. 2003;134:1057–1065
  205. Levy-Bohbot N, Merle C, Goudet P, et al. Prevalence, characteristics and prognosis of MEN 1-associated glucagonomas, VIPomas, and somatostatinomas: study from the GTE (Groupe des Tumeurs Endocrines) registry. Gastroenterol Clin Biol. 2004;28:1075–1081
  206. Norton JA, Fang TD, Jensen RT. Surgery for gastrinoma and insulinoma in multiple endocrine neoplasia type 1. J Natl Compr Canc Netw. 2006;4:148–153
  207. Cougard P, Goudet P, Peix JL, et al. [Insulinomas in multiple endocrine neoplasia type 1. Report of a series of 44 cases by the multiple endocrine neoplasia study group]. Ann Chir. 2000;125:118–123
  208. MacFarlane MP, Fraker DL, Alexander HR, et al. A prospective study of surgical resection of duodenal and pancreatic gastrinomas in multiple endocrine neoplasia-type 1. Surgery. 1995;118:973–980
  209. Akerstrom G, Hessman O, Hellman P, et al. Pancreatic tumours as part of the MEN-1 syndrome. Best Pract Res Clin Gastroenterol. 2005;19:819–830
  210. Sheppard BC, Norton JA, Doppman JL, et al. Management of islet cell tumors in patients with multiple endocrine neoplasia: a prospective study. Surgery. 1989;106:1108–1117
  211. Anlauf M, Garbrecht N, Henopp T, et al. Sporadic versus hereditary gastrinomas of the duodenum and pancreas: distinct clinico-pathological and epidemiological features. World J Gastroenterol. 2006;12:5440–5446
  212. Triponez F, Cadiot G. Non-functioning tumours of the pancreas in MEN1 patients. J Gastrointestin Liver Dis. 2007;16:295–296
  213. Fendrich V, Langer P, Waldmann J, et al. Management of sporadic and multiple endocrine neoplasia type 1 gastrinomas. Br J Surg. 2007;94:1331–1341
  214. Mignon M, Cadiot G, Rigaud D, et al. Management of islet cell tumors in patients with multiple endocrine neoplasia type 1. In:  Mignon M,  Jensen RT editor. Endocrine tumors of the pancreas: recent advances in research and management. Series: frontiers in gastrointestinal research. Volume 23:Basel, Switzerland: S. Karger; 1995;p. 342–359
  215. Triponez F, Goudet P, Dosseh D, et al. Is surgery beneficial for MEN1 patients with small (< or = 2 cm), nonfunctioning pancreaticoduodenal endocrine tumor? An analysis of 65 patients from the GTE. World J Surg. 2006;30:654–662
  216. Norton JA, Alexander HR, Fraker DL, et al. Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases or survival in patients with Zollinger-Ellison syndrome (ZES)?. Ann Surg. 2004;239:617–626
  217. Sugg SL, Norton JA, Fraker DL, et al. A prospective study of intraoperative methods to diagnose and resect duodenal gastrinomas. Ann Surg. 1993;218:138–144
  218. Norton JA. Surgery and prognosis of duodenal gastrinoma as a duodenal neuroendocrine tumor. Best Pract Res Clin Gastroenterol. 2005;19:699–704
  219. Norton JA, Jensen RT. Current surgical management of Zollinger-Ellison syndrome (ZES) in patients without multiple endocrine neoplasia-type 1 (MEN1). Surg Oncol. 2003;12:145–151
  220. Norton JA. Intraoperative methods to stage and localize pancreatic and duodenal tumors. Ann Oncol. 1999;10:182–184
  221. Maton PN, Mackem SM, Norton JA, et al. Ovarian carcinoma as a cause of Zollinger-Ellison syndrome (Natural history, secretory products and response to provocative tests). Gastroenterology. 1989;97:468–471
  222. Furihata M, Tagaya N, Kubota K. Laparoscopic enucleation of insulinoma in the pancreas: case report and review of the literature. Surg Laparosc Endosc Percutan Tech. 2001;11:279–283
  223. Ayav A, Bresler L, Brunaud L, et al. Laparoscopic approach for solitary insulinoma: a multicentre study. Langenbecks Arch Surg. 2005;390:134–140
  224. Toniato A, Meduri F, Foletto M, et al. Laparoscopic treatment of benign insulinomas localized in the body and tail of the pancreas: a single-center experience. World J Surg. 2006;30:1916–1919
  225. Frucht H, Norton JA, London JF, et al. Detection of duodenal gastrinomas by operative endoscopic transillumination: a prospective study. Gastroenterology. 1990;99:1622–1627
  226. Norton JA, Doppman JL, Jensen RT. Curative resection in Zollinger-Ellison syndrome: results of a 10-year prospective study. Ann Surg. 1992;215:8–18
  227. Norton JA, Doppman JL, Collen MJ, et al. Prospective study of gastrinoma localization and resection in patients with Zollinger-Ellison syndrome. Ann Surg. 1986;204:468–479
  228. Kato M, Imamura M, Hosotani R, et al. Curative resection of microgastrinomas based on the intraoperative secretin test. World J Surg. 2000;24:1425–1430
  229. Norton JA. Surgical treatment and prognosis of gastrinoma. Best Pract Res Clin Gastroenterol. 2005;19:799–805
  230. Nikfarjam M, Warshaw AL, Axelrod L, et al. Improved contemporary surgical management of insulinomas: a 25-year experience at the Massachusetts General Hospital. Ann Surg. 2008;247:165–172
  231. Butturini G, Bettini R, Missiaglia E, et al. Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma. Endocr Relat Cancer. 2006;13:1213–1221
  232. Shah T, Caplin M. Biotherapy for metastatic endocrine tumours. Best Pract Res Clin Gastroenterol. 2005;19:617–636
  233. Plockinger U, Wiedenmann B. Biotherapy. Best Pract Res Clin Endocrinol Metab. 2007;21:145–162
  234. Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev. 2004;25:458–511
  235. Delaunoit T, Rubin J, Neczyporenko F, et al. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumors. Mayo Clin Proc. 2005;80:502–506
  236. Panzuto F, Di Francesco V, Iannicelli E, et al. Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. Ann Oncol. 2006;17:461–466
  237. Fallucca P, Delle Fave G, Giangrande L, et al. Effect of somatostatin on gastrin, insulin and glucagon secretion in two patients with Zollinger-Ellison syndrome. J Endocrinol Invest. 1981;4:451–453
  238. Faiss S, Pape UF, Bohmig M, et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors—the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol. 2003;21:2689–2696
  239. Fazio N, de Braud F, Delle Fave G, et al. Interferon-alpha and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination?. Ann Oncol. 2007;18:13–19
  240. Forrer F, Valkema R, Kwekkeboom DJ, et al. Neuroendocrine tumors (Peptide receptor radionuclide therapy). Best Pract Res Clin Endocrinol Metab. 2007;21:111–129
  241. Van Essen M, Krenning EP, de Jong M, et al. Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol. 2007;46:723–734
  242. Kwekkeboom DJ, Teunissen JJ, Kam BL, et al. Treatment of patients who have endocrine gastroenteropancreatic tumors with radiolabeled somatostatin analogues. Hematol Oncol Clin North Am. 2007;21:561–573
  243. Virgolini I, Traub T, Novotny C, et al. Experience with indium-111 and yttrium-90-labeled somatostatin analogs. Curr Pharm Des. 2002;8:1781–1807
  244. Kaltsas GA, Papadogias D, Makras P, et al. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues. Endocr Relat Cancer. 2005;12:683–699
  245. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med. 2005;46(Suppl 1):62S–66S
  246. Valkema R, Pauwels S, Kvols LK, et al. Survival and response after peptide receptor radionuclide therapy with [(90)Y-DOTA(0),Tyr(3)]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med. 2006;36:147–156
  247. Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005;23:2754–2762
  248. O'Toole D, Ruszniewski P. Chemoembolization and other ablative therapies for liver metastases of gastrointestinal endocrine tumours. Best Pract Res Clin Gastroenterol. 2005;19:585–594
  249. Toumpanakis C, Meyer T, Caplin ME. Cytotoxic treatment including embolization/chemoembolization for neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab. 2007;21:131–144
  250. Arnold R, Trautmann ME, Creutzfeldt W, et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut. 1996;38:430–438
  251. Ruszniewski P, O'Toole D. Ablative therapies for liver metastases of gastroenteropancreatic endocrine tumors. Neuroendocrinology. 2004;80(Suppl 1):74–78
  252. Ramage JK, Davies AH, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut. 2005;54(Suppl 4):iv1–iv16
  253. Venook AP. Embolization and chemoembolization therapy for neuroendocrine tumors. Curr Opin Oncol. 1999;11:38–41
  254. Gupta S, Johnson MM, Murthy R, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer. 2005;104:1590–1602
  255. Osborne DA, Zervos EE, Strosberg J, et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol. 2006;13:572–581
  256. Ho AS, Picus J, Darcy MD, et al. Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors. AJR Am J Roentgenol. 2007;188:1201–1207
  257. Sarmiento JM, Que FG. Hepatic surgery for metastases from neuroendocrine tumors. Surg Oncol Clin North Am. 2003;12:231–242
  258. Falconi M, Bettini R, Boninsegna L, et al. Surgical strategy in the treatment of pancreatic neuroendocrine tumors. JOP. 2006;7:150–156
  259. Carty SE, Jensen RT, Norton JA. Prospective study of aggressive resection of metastatic pancreatic endocrine tumors. Surgery. 1992;112:1024–1031
  260. Sarmiento JM, Heywood G, Rubin J, et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003;197:29–37
  261. House MG, Cameron JL, Lillemoe KD, et al. Differences in survival for patients with resectable versus unresectable metastases from pancreatic islet cell cancer. J Gastrointest Surg. 2006;10:138–145
  262. Musunuru S, Chen H, Rajpal S, et al. Metastatic neuroendocrine hepatic tumors: resection improves survival. Arch Surg. 2006;141:1000–1004
  263. Moug SJ, Leen E, Horgan PG, et al. Radiofrequency ablation has a valuable therapeutic role in metastatic VIPoma. Pancreatology. 2006;6:155–159
  264. Mazzaglia PJ, Berber E, Milas M, et al. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery. 2007;142:10–19
  265. Gillams A, Cassoni A, Conway G, et al. Radiofrequency ablation of neuroendocrine liver metastases: the Middlesex experience. Abdom Imaging. 2005;30:435–441
  266. Elvin A, Skogseid B, Hellman P. Radiofrequency ablation of neuroendocrine liver metastases. Abdom Imaging. 2005;30:427–434
  267. Arnold R, Rinke A, Schmidt C, et al. Chemotherapy. Best Pract Res Clin Gastroenterol. 2005;19:649–656
  268. Kouvaraki MA, Ajani JA, Hoff P, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol. 2004;22:4762–4771
  269. Moertel CG, Hanley JA, Johnson LA. Streptozotocin alone compared with streptozotocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1980;303:1189–1194
  270. Moertel CG, Lefkopoulo M, Lipsitz S, et al. Streptozotocin-doxorubicin, streptozotocin-flourouracil or chlorozotocin in the treatment of advanced islet cell carcinoma. N Engl J Med. 1992;326:519–523
  271. von Schrenck T, Howard JM, Doppman JL, et al. Prospective study of chemotherapy in patients with metastatic gastrinoma. Gastroenterology. 1988;94:1326–1334
  272. Cheng PN, Saltz LB. Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer. 1999;86:944–948
  273. Ron D, Kazanietz MG. New insights into the regulation of protein kinase C and novel phorbol ester receptors. FASEB J. 1999;13:1658–1676
  274. Moertel CG, Kvols LK, O'Connell MJ, et al. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin (Evidence of major therapeutic activity in the anaplastic variants of these neoplasms). Cancer. 1991;68:227–232
  275. Hainsworth JD, Spigel DR, Litchy S, et al. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study. J Clin Oncol. 2006;24:3548–3554
  276. Fjallskog ML, Lejonklou MH, Oberg KE, et al. Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin Cancer Res. 2003;9:1469–1473
  277. Wulbrand U, Wied M, Zofel P, et al. Growth factor receptor expression in human gastroenteropancreatic neuroendocrine tumours. Eur J Clin Invest. 1998;28:1038–1049
  278. Peghini PL, Iwamoto M, Raffeld M, et al. Overexpression of epidermal growth factor and hepatocyte growth factor receptors in a proportion of gastrinomas correlates with aggressive growth and lower curability. Clin Cancer Res. 2002;8:2273–2285
  279. Furukawa M, Raffeld M, Mateo C, et al. Increased expression of insulin-like growth factor I (IGF-1) and/or its receptor (IGF-1R) in gastrinomas is associated with low curability, increased growth and development of metastases. Cancer Res. 2005;11:3233–3242
  280. Yao JC. Molecular targeted therapy for carcinoid and islet-cell carcinoma. Best Pract Res Clin Endocrinol Metab. 2007;21:163–172
  281. Strosberg JR, Kvols LK. A review of the current clinical trials for gastroenteropancreatic neuroendocrine tumours. Expert Opin Investig Drugs. 2007;16:219–224
  282. Chan JA, Kulke MH. Emerging therapies for the treatment of patients with advanced neuroendocrine tumors. Expert Opin Emerg Drugs. 2007;12:253–270
  283. Yao JC, Zhang JX, Rashid A, et al. Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res. 2007;13:234–240
  284. Hopfner M, Sutter AP, Gerst B, et al. A novel approach in the treatment of neuroendocrine gastrointestinal tumours (Targeting the epidermal growth factor receptor by gefitinib (ZD1839)). Br J Cancer. 2003;89:1766–1775
  285. Kulke M, Lenz HJ, Meropol NJ, et al. A phase 2 study to evaluate the efficacy and safety of SU11248 in patients with unresectable neuroendocrine tumors (NET): a phase 11 consortium (P2C) study. J Clin Oncol. 2005;23:310s
  286. Hobday TJ, Holen K, Donehower R, et al. A phase II trial of gefitinib in patients with progressive metastatic neuroendocrine tumors: a phase II consortium study. J Clin Oncol. 2006;24:A4043
  287. Duran I, Kortmansky J, Singh D, et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer. 2006;95:1148–1154
  288. Kimmig BN. Radiotherapy for gastroenteropancreatic neuroendocrine tumors. Ann N Y Acad Sci. 1994;733:488–495
  289. Strosberg J, Hoffe S, Gardner N, et al. Effective treatment of locally advanced endocrine tumors of the pancreas with chemoradiotherapy. Neuroendocrinology. 2007;85:216–220
  290. Pascher A, Klupp J, Neuhaus P. Transplantation in the management of metastatic endocrine tumours. Best Pract Res Clin Gastroenterol. 2005;19:637–648
  291. Olausson M, Friman S, Herlenius G, et al. Orthotopic liver or multivisceral transplantation as treatment of metastatic neuroendocrine tumors. Liver Transpl. 2007;13:327–333
  292. Le Treut YP, Delpero JR, Dousset B, et al. Results of liver transplantation in the treatment of metastatic neuroendocrine tumors (A 31-case French multicentric report). Ann Surg. 1997;225:355–364
  293. Lehnert T. Liver transplantation for metastatic neuroendocrine carcinoma. Transplantation. 1998;66:1307–1312
  294. Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9:61–72
  295. de Herder WW, O'Toole D, Rindi G, et al. ENETS consensus guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumors: part 2—midgut and hindgut tumors. Neuroendocrinology. 2008;87:1–63
  296. Rindi G, Kloppel G, Couvelard A, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2007;451:757–762
  297. Kaplan EL, Horvath K, Udekwu A, et al. Gastrinomas: a 42-year experience. World J Surg. 1990;14:365–375
  298. Farley DR, Van Heerden JA, Grant CS, et al. The Zollinger-Ellison syndrome (A collective surgical experience). Ann Surg. 1992;215:561–569
  299. Mignon M, Cadiot G. Diagnostic and therapeutic criteria in patients with Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1. J Intern Med. 1998;243:489–494
  300. Galbut DL, Markowitz AM. Insulinoma: diagnosis, surgical management and long-term follow- up (Review of 41 cases). Am J Surg. 1980;139:682–690
  301. Dizon AM, Kowalyk S, Hoogwerf BJ. Neuroglycopenic and other symptoms in patients with insulinomas. Am J Med. 1999;106:307–310
  302. Soga J, Yakuwa Y, Osaka M. Insulinomas/hypoglycemic syndrome: a statistical evaluation of 1085 reported cases of a Japanese series. J Exp Clin Cancer Res. 1998;17:379–388
  303. Fajans SS, Vinik AI. Insulin-producing islet cell tumors. Endocrinol Metab Clin North Am. 1989;18:45–74
  304. Wiedmann MW, Caca K. Molecularly targeted therapy for gastrointestinal cancer. Curr Cancer Drug Targets. 2005;5:171–193
  305. Smolewski P. Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway. Anticancer Drugs. 2006;17:487–494
  306. Dancey JE. Therapeutic targets: MTOR and related pathways. Cancer Biol Ther. 2006;5:1065–1073
  307. Rocha-Lima CM, Soares HP, Raez LE, et al. EGFR targeting of solid tumors. Cancer Control. 2007;14:295–304
  308. Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer. 2004;11:689–708

 The authors disclose the following: this work is partially supported by the Intramural Program of the NIDDK, National Institutes of Health.

PII: S0016-5085(08)00868-8

doi: 10.1053/j.gastro.2008.05.047

Gastroenterology
Volume 135, Issue 5 , Pages 1469-1492 , November 2008

Article Tools

* Image Usage & Resolution